Imagine a world where infants who’ve suffered a stroke can regain function and skills, defying what was once considered a grim prognosis. But here’s where it gets controversial: a groundbreaking study suggests that high-dose, goal-directed therapy, combined with restricting the use of the stronger arm, can lead to significant improvements in these young patients. And this is the part most people miss—even children receiving standard care showed unexpected progress, sparking questions about the best approach to early stroke recovery.
The American Heart Association recently highlighted a study that could change the way we treat infants and toddlers who’ve experienced a stroke. Researchers focused on 167 stroke survivors under three years old with marked impairment in one arm. These children were randomly assigned to one of three groups: high-dose therapy, moderate-dose therapy, or usual care. The therapy in question, called I-ACQUIRE, combines intensive, task-oriented physical therapy with the strategic restriction of the stronger arm to encourage use of the affected side.
Here’s the kicker: after six months, children in the high-dose group showed larger gains in skills and daily function compared to those in the moderate-dose or usual care groups. But what’s truly surprising is that many children in the usual care group—typically receiving just one hour each of occupational and physical therapy weekly—also demonstrated significant improvement. This raises a thought-provoking question: Is the intensity of therapy the only factor driving progress, or are there other mechanisms at play?
The study, presented at the American Stroke Association’s International Stroke Conference 2026, sheds light on perinatal arterial ischemic stroke (PAIS), the most common form of stroke in children. PAIS causes hemiparesis, a condition characterized by limited voluntary motor control on one side of the body. Constraint-Induced Movement Therapy (CIMT), a rehabilitation approach designed to rewire the brain after injury, was adapted for this study to focus on very young children. The therapy included intensive motor exercises, guided by learning principles, and the use of a lightweight cast to restrict the stronger arm.
This is the first study to evaluate CIMT in infants and toddlers with PAIS, delivered in their homes with parental involvement. But here’s the controversial part: while the high-dose group showed the most significant gains, the usual care group’s unexpected progress challenges the notion that intensive therapy is the only path to recovery. Could there be untapped potential in standard care, or are these improvements merely a result of natural development?
Study author Sharon Ramey, Ph.D., notes that this research fills a critical knowledge gap. Previously, treatment recommendations for infants and toddlers were based on studies involving older children with cerebral palsy, which lacked relevance to this specific population. Now, we know that high-dose therapy is safe, well-received, and effective—but the usual care group’s progress demands further investigation.
The study’s findings are promising yet complex. Children in both high- and moderate-dose groups gained an average of 3 new skills, compared to just 1 in the usual care group. However, these gains were smaller than expected, possibly due to the variability in how children with PAIS respond to treatment. Parents reported meaningful improvements in everyday activities, such as manipulating toys and performing self-help tasks, but the usual care group’s real-world progress remains less clear.
Here’s where it gets even more intriguing: Ramey suggests that the potential for recovery in infants far exceeds previous expectations. Parents reported seeing changes in their children that surpassed what they’d been told was possible, leading them to raise their expectations for their child’s future. This raises another question: Are we underestimating the resilience of the infant brain, and could this change how we approach early intervention?
The study’s strengths include its careful design, close monitoring of participants, and focus on a previously understudied population. However, limitations exist, such as the selection of U.S. sites based on resources and interest, which may not represent all care settings. Additionally, some children enrolled based on parental reports of PAIS were not confirmed by specialists, reducing the sample size to 167.
So, what does this mean for the future of pediatric stroke treatment? While high-dose therapy shows clear benefits, the usual care group’s progress opens the door to new questions. Should we reevaluate standard care protocols, or is intensive therapy still the gold standard? And how can we better identify which children will benefit most from these interventions?
We want to hear from you: Do you think high-dose therapy should become the norm for infants with early stroke, or is there value in refining standard care? Share your thoughts in the comments—let’s spark a conversation that could shape the future of pediatric rehabilitation.
